Ghrelin, leptin and adiponectin levels in Gaucher disease type I patients on enzyme replacement therapy

Clinical Nutrition

Volumn 34, Issue 4, 2015, Pages 727-731

  Doneda, Divair ^a   Lopes, André L ^a,b   Teixeira, Bruno C ^a   Mittelstadt, Suzana D ^a   Moulin, Cileide C ^a   Schwartz, Ida V D ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b University Center UNIVATES   (Brazil)

Author keywords

Adiponectin; Gaucher disease type I; Ghrelin; Insulin; Leptin

Indexed keywords

ADIPONECTIN; GHRELIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMIGLUCERASE; INSULIN; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TALIGLUCERASE ALFA; TRIACYLGLYCEROL;

ADIPONECTIN BLOOD LEVEL; ADULT; AGE; ARTICLE; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; ENZYME REPLACEMENT; FEMALE; GAUCHER DISEASE; GHRELIN BLOOD LEVEL; HORMONE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LEPTIN BLOOD LEVEL; MALE; METABOLIC SYNDROME X; OBESITY; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SEX; WAIST CIRCUMFERENCE; BLOOD; COMPLICATION; MIDDLE AGED; NUTRITIONAL ASSESSMENT; NUTRITIONAL STATUS; OVERWEIGHT; PROCEDURES; YOUNG ADULT;

ADIPONECTIN; ADULT; BODY MASS INDEX; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; ENZYME REPLACEMENT THERAPY; FEMALE; GAUCHER DISEASE; GHRELIN; HUMANS; INSULIN RESISTANCE; LEPTIN; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NUTRITION ASSESSMENT; NUTRITIONAL STATUS; OVERWEIGHT; TRIGLYCERIDES; YOUNG ADULT;

EID: 84930762861     PISSN: 02615614     EISSN: 15321983     Source Type: Journal    
DOI: 10.1016/j.clnu.2014.08.010     Document Type: Article

References (44)

1. Thomas A.S., Mehta A., Hughes D.A. Gaucher disease: haematological presentations and complications. Br J Haematol 2014, 165(4):427-440. 10.1111/bjh.12804.
2. Rosenbloom B.E., Weinreb N.J. Gaucher disease: a comprehensive review. Crit Rev Oncog 2013, 18(3):163-175.
3. Stein P., Yu H., Jain D., Mistry P.K. Hyperferritinemia and iron overload in type 1 Gaucher disease. Am J Hematol 2010, 85(7):472-476. 10.1002/ajh.21721.
4. Barton D.J., Ludman M.D., Benkov K., Grabowski G.A., LeLeiko N.S. Resting energy expenditure in Gaucher's disease type 1: effect of Gaucher's cell burden on energy requirements. Metabolism 1989, 38(12):1238-1243.
5. Corssmit E.P., Hollak C.E., Endert E., van Oers M.H., Sauerwein H.P., Romijn J.A. Increased basal glucose production in type 1 Gaucher's disease. JClin Endocrinol Metab 1995, 80(9):2653-2657.
6. Doneda D., Lopes A.L., Oliveira A.R., Netto C.B., Moulin C.C., Schwartz I.V. Gaucher disease type I: assessment of basal metabolic rate in patients from southern Brazil. Blood Cells Mol Dis 2011, 46(1):42-46. 10.1016/j.bcmd.2010.10.008.
7. Langeveld M., Scheij S., Dubbelhuis P., Hollak C.E., Sauerwein H.P., Simons P., et al. Very low serum adiponectin levels in patients with type 1 Gaucher disease without overt hyperglycemia. Metabolism 2007, 56:314-319.
8. Hollak C.E., Corssmit E.P., Aerts J.M., Endert E., Sauerwein H.P., Romijn J.A., et al. Differential effects of enzyme supplementation therapy on manifestations of type 1 Gaucher disease. Am J Med 1997, 103(3):185-191.
9. Langeveld M., Ghauharali K.J., Sauerwein H.P., Ackermans M.T., Groener J.E., Hollak C.E., et al. Type I Gaucher disease, a glycosphingolipid storage disorder, is associated with insulin resistance. JClin Endocrinol Metab 2008, 93(3):845-851.
10. Ucar S.K., Coker M., Argin M., Akman S., Kara S., Simsek D.G., et al. Across-sectional, mono-centric pilot study of insulin resistance in enzyme replacement therapy patients with Gaucher type I without overweight. Mol Genet Metab 2009, 96(1):50-51. 10.1016/j.ymgme.2008.10.001.
11. Groener J.E.M., Poorthuis B.J.H.M., Kuiper S., Hollak C.E.M., Aerts J.M.F.G. Plasma glucosylceramide and ceramide in type 1 Gaucher disease patients: correlations with disease severity and response to therapeutic intervention. Biochim Biophys Acta 2008, 1781(1-2):72-78.
12. Ghauharali-van der Vlugt K., Langeveld M., Poppema A., Kuiper S., Hollak C.E., Aerts J.M., et al. Prominent increase in plasma ganglioside GM3 is associated with clinical manifestations of type I Gaucher disease. Clin Chim Acta 2008, 389(1-2):109-113. 10.1016/j.cca.2007.12.001.
13. Langeveld M., de Fost M., Aerts J.M., Sauerwein H.P., Hollak C.E. Overweight, insulin resistance and type II diabetes in type I Gaucher disease patients in relation to enzyme replacement therapy. Blood Cells Mol Dis 2008, 17:1-5.
14. Doneda D., Netto C.B., Moulin C.C., Schwartz I.V. Effects of imiglucerase on the growth and metabolism of Gaucher disease type I patients: a systematic review. Nutr Metab (Lond) 2013 Apr 9, 10(1):34. 10.1186/1743-7075-10-34.
15. Read A., Donai D. New clinical genetics, 2nd revised edition 2010, Scion Publishing Ltd.
16. Alberti K.G., Eckel R.H., Grundy S.M., Zimmet P.Z., Cleeman J.I., Donato K.A., et al. Harmonizing the metabolic syndrome. A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120:1640-1645. 10.1161/CIRCULATIONAHA.109.192644.
17. Ford E.S., Schulze M.B., Pischon T., Bergmann M.M., Joost H.G., Boeing H. Metabolic syndrome and risk of incident diabetes: findings from the European Prospective Investigation into Cancer and Nutrition-Potsdam Study. Cardiovasc Diabetol 2008, 7:35. 10.1186/1475-2840-7-35.
18. Shaibi G.Q., Goran M.I. Examining metabolic syndrome definitions in overweight hispanic youth: a focus on insulin resistance. JPediatr 2008, 152(2):171-176. 10.1016/j.jpeds.2007.08.010.
19. Mlinar B., Marc J., Janez A., Pfeifer M. Molecular mechanisms of insulin resistance and associated diseases. Clin Chim Acta 2007, 375:20-35.
20. Shoelson S.E., Lee J., Goldfine A.B. Inflammation and insulin resistance. JClin Invest 2006, 116(7):1793-1801.
21. Hotamisligil G.S. Inflammation and metabolic disorders. Nature 2006, 444(7121):860-867.
22. Samuel V.T., Shulman G.I. Integrating mechanisms for insulin resistance: common threads and missing links. Cell 2012, 148(5):852-871. 10.1016/j.cell.2012.02.017.
23. Kojima M., Hosoda H., Date Y., Nakazato M., Matsuo H., Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999, 402(6762):656-660.
24. Castañeda T.R., Tong J., Datta R., Culler M., Tschöp M.H. Ghrelin in the regulation of body weight and metabolism. Front Neuroendocrinol 2010, 31(1):44-60. 10.1016/j.yfrne.2009.10.008.
25. Galic S., Oakhill J.S., Steinberg G.R. Adipose tissue as an endocrine organ. Mol Cell Endocrinol 2010, 316(2):129-139. 10.1016/j.mce.2009.08.018.
26. Amini P., Wadden D., Cahill F., Randell E., Vasdev S., Chen X., et al. Serum acylated ghrelin is negatively correlated with the insulin resistance in the CODING study. PLoS One 2012, 7(9):e45657. 10.1371/journal.pone.0045657.
27. Stengel A., Taché Y. Gastric peptides and their regulation of hunger and satiety. Curr Gastroenterol Rep 2012, 14(6):480-488. 10.1007/s11894-012-0291-3.
28. Adamczak M., Wiecek A. The adipose tissue as an endocrine organ. Semin Nephrol 2013, 33(1):2-13. 10.1016/j.semnephrol.2012.12.008.
29. Nishida M., Funahashi T., Shimomura I. Pathophysiological significance of adiponectin. Med Mol Morphol 2007, 40(2):55-67.
30. Matsuzawa Y. Establishment of a concept of visceral fat syndrome and discovery of adiponectin. Proc Jpn Acad Ser B Phys Biol Sci 2010, 86(2):131-141.
31. Ziemke F., Mantzoros C.S. Adiponectin in insulin resistance: lessons from translational research. Am J Clin Nutr 2010, 91(1):258S-261S. 10.3945/ajcn.2009.28449C.
32. WHO World Health Organization Obesity: preventing and managing the global epidemic. Report a WHO consultation. WHO technical report series: 894 2000, WHO, Geneva.
33. International Diabetes Federation - IDF The IDF consensus worldwide definition of the metabolic syndrome 2005, Avaliable from:. http://www.idf.org/webdata/docs/Metabolic_syndrome_definition.pdf.
34. Matthews D., Hosker J.P., Rudenski A.S., Naylor B.A., Trecher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and b-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 1985, 28:412-419.
35. Geloneze B., Vasques A.C., Stabe C.F., Pareja J.C., Rosado L.E., Queiroz E.C., et al. HOMA1-IR and HOMA2-IR indexes in identifying insulin resistance and metabolic syndrome - Brazilian metabolic syndrome study (BRAMS). Arq Bras Endocrinol Metabol 2009, 53(2):281-287.
36. Stein P., Yang R., Liu J., Pastores G.M., Mistry P.K. Evaluation of high density lipoprotein as a circulating biomarker of Gaucher disease activity. JInherit Metab Dis 2011, 2(34):429-437. 10.1007/s10545-010-9271-7.
37. Tschop M., Weyer C., Tataranni P.A., Devanarayan V., Ravussin E., Heiman M.L. Circulating ghrelin levels are decreased in human obesity. Diabetes 2001, 50:707-709.
38. English P.J., Ghatei M.A., Malik I.A., Bloom S.R., Wilding J.P. Food fails to suppress ghrelin levels in obese humans. JClin Endocrinol Metab 2002, 87:2984.
39. Martins M.C., Faleiro L.L., Fonse A. Relationship between leptin and body mass and metabolic syndrome in an adult population. Rev Port Cardiol 2012, 31(11):711-719. 10.1016/j.repc.2012.08.002.
40. Boven L.A., van Meurs M., Boot R.G., Mehta A., Boon L., Aerts J.M., et al. Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated. Am J Clin Pathol 2004, 122(3):359-369.
41. Vigitel Brazil 2013: Protective and risk factors for chronic diseases by telephone survey. http://www.saude.gov.br/bvs.
42. de Carvalho Vidigal F., Bressan J., Babio N., Salas-Salvadó J. Prevalence of metabolic syndrome in Brazilian adults: a systematic review. BMC Public Health 2013 Dec 18, 13:1198. 10.1186/1471-2458-13-1198.
43. Chavez J.A., Siddique M.M., Wang S.T., Ching J., Shayman J.A., Summers S.A. Ceramides and glucosylceramides are independent antagonists of insulin signaling. JBiol Chem 2014, 289(2):723-734. 10.1074/jbc.M113.522847.
44. Aerts J.M., Boot R.G., van Eijk M., Groener J., Bijl N., Lombardo E., et al. Glycosphingolipids and insulin resistance. Adv Exp Med Biol 2011, 721:99-119. 10.1007/978-1-4614-0650-1_7.